Pediatric Flu & Neurological Complications: Vaccination Gaps
- Here's a breakdown of the key facts from the provided text, organized for clarity:
- * Total Pediatric Flu Deaths: 1,840 (2010-11 thru 2024-25 seasons) * IAE (Influenza-Associated Encephalopathy) Cases: 166 (9% of the total deaths) * 2024-25 Season (through Feb 8, 2025):...
- * Antiviral Therapy: Given to 84% of patients (mostly after hospital admission).
Here’s a breakdown of the key facts from the provided text, organized for clarity:
Key Findings & Statistics (2010-2025):
* Total Pediatric Flu Deaths: 1,840 (2010-11 thru 2024-25 seasons)
* IAE (Influenza-Associated Encephalopathy) Cases: 166 (9% of the total deaths)
* 2024-25 Season (through Feb 8, 2025): 9 of 68 fatal pediatric flu cases (13%) had IAE, 4 confirmed as ANE (Acute Necrotizing encephalopathy).
* IAE Group (109 cases):
* 74% admitted to ICU
* 54% required mechanical ventilation
* 19% died
* ANE Subgroup: 41% death rate; survivors often had lasting neurological problems.
* Age of Affected Children: Median age 5 years (IAE) and 4 years (ANE).
* Underlying Health Conditions: More than half of the children did not have pre-existing health conditions.
* Onset of neurological Symptoms: Rapid - within 2 days of initial flu symptoms.
* Vaccination Rates: Very low – 16% of IAE patients and 13% of ANE patients were vaccinated at least 2 weeks prior to illness. this aligns with a general decreasing trend in US childhood flu vaccination rates.
Treatment:
* Antiviral Therapy: Given to 84% of patients (mostly after hospital admission).
* ANE Treatment: Immunomodulatory treatments (corticosteroids, IVIG, plasma exchange) were used.
* Hospital Stay: Long – ANE survivors averaged nearly 1 month of inpatient care.
Gaps in Surveillance:
* Lack of a nationally standardized surveillance system to track flu-associated neurological complications (IAE and ANE).
* Current surveillance focuses primarily on fatal cases, potentially underreporting severe, non-fatal outcomes.
* CDC recommends incorporating IAE and ANE monitoring into flu surveillance.
Role of Pharmacists:
* Early Recognition: Be alert for children with fever/respiratory illness who develop seizures, altered mental status, or decreased consciousness.
* Antiviral Promotion: Encourage prompt antiviral initiation, especially for high-risk children.
* Vaccine Advocacy: Pharmacists are key in advising about vaccines, emphasizing both respiratory and neurological risks. Increasing vaccine uptake is crucial.
Main Takeaway:
the text highlights a concerning trend of neurological complications (IAE and ANE) following influenza infection in children, even in those without underlying health conditions. Low vaccination rates and gaps in surveillance are significant issues. Pharmacists are positioned to play a vital role in prevention and early intervention.